Table 3 CDKN2B-AS1 (rs1333049) and ZFHX3 (rs2106261) gene polymorphisms of COVID-19 patients and healthy controls in different models

CDKN2B-AS1 (rs1333049)

GG® vs. GC + CC(Dominant)

0.233

1.625(0.732–3.608)

< 0.001^*

6.217(3.167–12.204)

< 0.001^*

3.826(2.113–6.926)

GG + GC® vs. CC (Recessive)

0.071

0.507(0.242–1.059)

0.621

1.197(0.586–2.445)

0.007^*

2.364(1.253–4.459)

GG vs. GC ® (Codominant-1)

0.098

2.0(0.880–4.544)

< 0.001^*

6.902(3.451–13.803)

< 0.001^*

3.451(1.843–6.463)

GG vs. CC® (Codominant-2)

0.790

0.875(0.327– 2.341)

0.001*

4.278(1.751–10.453)

< 0.001^*

4.889(2.287–10.451)

GC vs. GG + CC® (overdominant)

0.014^*

0.464(0.251– 0.860)

< 0.001^*

0.247(0.143–0.426)

0.02^*

0.531(0.318–0.887)

ZFHX3 (rs2106261)

CC® vs. CT + TT (Dominant)

0.112

1.670(0.887–3.142)

0.141

1.495(0.876–2.550)

0.702

0.895(0.507–1.579)

CC + CT ® vs. TT (Recessive)

1.000

–

0.549

0.395(0.019–8.304)

0.549

0.395(0.019–8.304)

CC® vs. CT (Codominant-1)

0.112

1.670(0.887–3.142)

0.108

1.554(0.908–2.659)

0.806

0.931(0.526–1.646)

CC® vs. TT (Codominant-2)

0.935

1.177(0.023–60.278)

0.613

0.455(0.022–9.629)

0.541

0.387(0.018–8.167)

CT vs. CC + TT ® (overdominant)

0.112

0.599(0.318–1.127)

0.095

0.634(0.370–1.083)

0.847

1.058(0.598–1.870)